Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

• Published in: The oncologist (Dayton, Ohio) Vol. 27; no. 4; pp. e357 - e361
• Main Authors: Guven, Deniz C, Sahin, Taha K, Akın, Serkan, Uckun, Fatih M
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 05.04.2022
• Subjects: Antibodies, Viral; Blood diseases; Brief Communications; Care and treatment; Coronaviruses; COVID-19 - prevention & control; COVID-19 Vaccines - therapeutic use; Database industry; Development and progression; Diagnosis; Evaluation; Health aspects; Hematologic Neoplasms - complications; Humans; Immune response; Immunization; Leukemia; Patient outcomes; SARS-CoV-2; Seroconversion; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Vaccination; Turkey; COVID-19; hematological malignancies; SARS-CoV-2; vaccine; antibody

Abstract Introduction The leading professional organizations in the field of hematology have recommended severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccination for all patients with hematologic malignancies notwithstanding efficacy concerns. Here we report a systematic literature r...